Tag

Baxter International

All articles tagged with #baxter international

health1 year ago

IV Fluid Shortage Strains Hospitals as Production Resumes Post-Helene

A nationwide shortage of intravenous (IV) fluids, exacerbated by Hurricane Helene's impact on Baxter International's North Carolina facility, is forcing hospitals to adopt new conservation strategies. With production halted and rationing in place, hospitals are reducing IV fluid usage by 55% and exploring alternatives like push medications. Health officials are also re-evaluating patient hydration needs to manage the crisis, which may persist through 2024. The shortage highlights the need for innovative approaches to patient care and resource management.

finance2 years ago

Investment Strategist Recommends Buying Baxter Over Eli Lilly Amidst GLP-1 Craze

Great Hill Capital Chairman and Managing Member Tom Hayes suggests buying Baxter International (BAX) as a play on the GLP-1 hype, citing its aggressive sell-off, tremendous valuation, and potential catalysts for stock recovery. On the other hand, Hayes advises against buying Eli Lilly (LLY), stating that the stock has already priced in positive news, faces increased competition, and uncertainty regarding insurance coverage for obesity drugs.

business2 years ago

Baxter Sells BioPharma Solutions Business for $4.25B.

Baxter International has signed a definitive agreement to sell its BioPharma Solutions (BPS) business to Advent International and Warburg Pincus for $4.25bn in cash. The deal is expected to close in H2 2023, subject to regulatory approvals. BPS has been a leading provider of sterile contract manufacturing solutions, parenteral delivery systems and customized support services to the pharma and biotech industries for decades. As a standalone company and in partnership with Advent and Warburg Pincus, BPS will operate as a premier, independent end-to-end CDMO providing a range of services for clients, from clinical research to commercial deployment.

business2 years ago

Warburg and Advent Leading Bid for Baxter's Biopharma Unit in Multi-Billion Dollar Deal

Private equity firms Warburg Pincus and Advent International are in advanced talks to acquire Baxter International's biopharma solutions business in a deal that could reach or exceed $4 billion. The buyout consortium has turned to other private equity firms to help fund the deal as direct lenders. Baxter may still opt to sell to another bidder or keep the business. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.